Endoscopic Band Ligation as First‑Line Therapy for Gastric Antral Vascular Ectasia

Primary Guideline Recommendation

The 2025 Canadian Association of Gastroenterology guideline recommends endoscopic band ligation (EBL) as the preferred endoscopic modality for patients with gastric antral vascular ectasia (GAVE) causing chronic upper‑gastrointestinal bleeding, based on the most recent high‑quality evidence. 1

EBL requires fewer treatment sessions, achieving obliteration of GAVE in a mean of 2.6 sessions compared with 3.8 sessions for argon plasma coagulation (APC). 2
Patients treated with EBL experience a greater hemoglobin rise, with a mean increase of 0.6 g/dL over thermal therapies (95 % CI 0.17–1.00). 2, 3
EBL reduces transfusion needs, lowering the mean number of packed red‑cell units by 2.3 units relative to thermal methods (95 % CI ‑4.11 to ‑2.48). 2, 3
The safety profile of EBL is favorable; adverse events are rare and limited to mild symptoms such as nausea, vomiting, and abdominal pain. 2, 3

The 2019 International Consensus Group guidelines do not address endoscopic management of GAVE, focusing instead on peptic ulcer disease, making the 2025 CAG guideline the definitive current standard. 4

All patients with GAVE and iron‑deficiency anemia should receive iron repletion therapy. 2, 3
Oral iron is appropriate for mild‑to‑moderate iron depletion when tolerated. 2, 3
Intravenous iron is recommended for severe depletion, profound anemia, or when oral iron is intolerable. 2, 3

No pharmacologic agents have demonstrated proven efficacy for GAVE; therefore, they are not recommended as primary therapy. 2, 3
Tranexamic acid may be considered for mild bleeding owing to its low harm potential, although supporting evidence is limited. 5

Endoscopic therapy should be directed at active bleeding or high‑risk lesions identified during diagnostic endoscopy. 5
Routine, systematic repeated ablative endoscopy lacks sufficient supporting data and should be avoided. 5

Follow‑up endoscopy should be scheduled based on clinical indicators of recurrence (e.g., return of anemia, increased transfusion requirements, declining hemoglobin trends). 2, 3

GAVE frequently coexists with cirrhosis, chronic kidney disease, systemic sclerosis, and other autoimmune diseases; these comorbidities should be managed concurrently, although they do not alter the primary endoscopic treatment strategy. 2, 3

GAVE is a recognized source of iron‑deficiency anemia due to chronic, often occult gastrointestinal blood loss from capillary‑type vascular malformations in the gastric antrum. [6][7]

All individuals with GAVE‑related iron‑deficiency anemia should receive iron repletion in addition to definitive lesion treatment. [6][7]
Oral iron supplementation is recommended initially for patients with mild‑to‑moderate iron depletion who can tolerate it. 6
Intravenous iron is indicated when oral iron is ineffective, when bleeding persists despite oral therapy, or in cases of severe anemia. [6][7]

Endoscopic therapy becomes the primary intervention when iron replacement alone does not correct anemia. [6][7]

Argon plasma coagulation (APC) remains an acceptable thermal endoscopic option when the preferred technique (e.g., band ligation) is unavailable or contraindicated. [6][7]

Systemic bevacizumab has demonstrated substantial benefit in hereditary hemorrhagic telangiectasia, highlighting a contrast with the lack of proven pharmacologic agents for primary GAVE therapy. 8